Current Hematologic Malignancy Reports

, Volume 14, Issue 3, pp 164–170 | Cite as

Integrative Approaches to Managing Myeloproliferative Neoplasms: the Role of Nutrition, Exercise, and Psychological Interventions

  • Prathibha Surapaneni
  • Robyn M. ScherberEmail author
Myeloproliferative Neoplasms (B Stein, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Myeloproliferative Neoplasms


Purpose of Review

Myeloproliferative neoplasms (MPNs) have a high symptom burden that affects functional status, emotional well-being, and quality of life for patients. Symptom control continues to be a challenging therapeutic goal despite available pharmacologic interventions. The goal of this review is to detail recent efforts that have focused on non-pharmacologic interventions, such as wholistic or integrative medicine, as an adjunctive method to alter symptom burden in this population.

Recent Findings

We discuss the ongoing physical, nutritional, and psychological interventional efforts which represent promising non-traditional interventions to date to help reduce symptom in MPN patients. In this article, we highlight the early promising data and importance of these various non-pharmacological interventions to dampen symptom burden and reduce disease-related inflammation.


Nonpharmacologic interventions represent promising therapeutic strategies to alter traditional MPN treatment paradigms and improve MPN patient care.


Myeloproliferative neoplasms Hematopoietic stem cells Chronic inflammation Symptom burden Quality of life Non-pharmacologic interventions Integrative medicine 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    O'Sullivan J and Mead AJ. Heterogeneity in myeloproliferative neoplasms: causes and consequences. Adv Biol Regul. 2018.
  2. 2.••
    Scherber RM, Kosiorek HE, Senyak Z, Dueck AC, Clark MM, Boxer MA, et al. Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. Cancer. 2016;122(3):477–85 Details the multifactorial nature of symptom burden in MPN populations and details the early findings of patient-directed integrative treatments to impact symptom burden and fatigue.CrossRefGoogle Scholar
  3. 3.••
    Geyer HL, et al. Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development. Mediat Inflamm. 2015;2015:284706 This study summarizes the data that demonstrates the link between MPN symptoms to disease-related inflammation.CrossRefGoogle Scholar
  4. 4.
    Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098–103.CrossRefGoogle Scholar
  5. 5.
    Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. BLood. 2011;118(2):401–8.CrossRefGoogle Scholar
  6. 6.
    Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68–76.CrossRefGoogle Scholar
  7. 7.
    Mesa RA, Scherber RM, Geyer HL. Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors. Leuk Lymphoma. 2015;56(7):1989–99.CrossRefGoogle Scholar
  8. 8.
    Geyer H, et al. Symptom burden profile in myelofibrosis patients with thrombocytopenia: lessons and unmet needs. 2015;126(23):4080–4080.Google Scholar
  9. 9.
    Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN landmark survey. Ann Hematol. 2017;96(10):1653–65.CrossRefGoogle Scholar
  10. 10.
    Geyer, HL and R.A. Mesa, Therapy for myeloproliferative neoplasms: when, which agent, and how?. 2014;124:(24): p. 3529–3537.Google Scholar
  11. 11.
    Huberty J, et al. Online-streamed yoga as a non-pharmacologic symptom management approach in myeloproliferative neoplasms. 2016;128(22):5478–5478.Google Scholar
  12. 12.
    Geyer H, et al. Symptomatic profiles of patients with polycythemia vera: implication of inadequately controlled disease. 2016;34(2):151–159.
  13. 13.
    Geyer H, et al. Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease. 2016;34(2):151–159.Google Scholar
  14. 14.
    Craver BM, et al. The critical role of inflammation in the pathogenesis and progression of myeloid malignancies. Cancers (Basel) 2018;10(4).
  15. 15.
    Scherber R, et al. The relationship of BMI to symptom burden in the myeloproliferative neoplasms. Haematologia. 2017;102(S2):215667.Google Scholar
  16. 16.
    Marty C, Lacout C, Droin N, le Couédic JP, Ribrag V, Solary E, et al. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia. 2013;27(11):2187–95.CrossRefGoogle Scholar
  17. 17.
    McFarland DC, Shaffer KM, Polizzi H, Mascarenhas J, Kremyanskaya M, Holland J, et al. Associations of physical and psychologic symptom burden in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Psychosomatics. 2018;59(5):472–80.CrossRefGoogle Scholar
  18. 18.••
    Brochmann N, Flachs EM, Christensen AI, Bak M, Andersen CL, Juel K, et al. Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark. Clin Epidemiol. 2019;11:23–33 Demonstrates the importance of cognitive and emotional issues in MPN patients.CrossRefGoogle Scholar
  19. 19.
    Eckert R, et al. A pilot study of online yoga to improve fatigue and quality of life in myeloproliferative neoplasm patients. 2017;130(Suppl 1):3443–3.Google Scholar
  20. 20.
    Simister HD, Tkachuk GA, Shay BL, Vincent N, Pear JJ, Skrabek RQ. Randomized controlled trial of online acceptance and commitment therapy for fibromyalgia. J Pain. 2018;19(7):741–53.CrossRefGoogle Scholar
  21. 21.
    Jacobsen HB, Kallestad H, Landrø NI, Borchgrevink PC, Stiles TC. Processes in acceptance and commitment therapy and the rehabilitation of chronic fatigue. Scand J Psychol. 2017;58(3):211–20.CrossRefGoogle Scholar
  22. 22.
    Vowles KE, et al. An analysis of within-treatment change trajectories in valued activity in relation to treatment outcomes following interdisciplinary acceptance and commitment therapy for adults with chronic pain. Behav Res Ther. 2019;115:46–54.
  23. 23.
    Kangas M, McDonald S, Williams JR, Smee RI. Acceptance and commitment therapy program for distressed adults with a primary brain tumor: a case series study. Support Care Cancer. 2015;23(10):2855–9.CrossRefGoogle Scholar
  24. 24.
    Mosher CE, Secinti E, Li R, Hirsh AT, Bricker J, Miller KD, et al. Acceptance and commitment therapy for symptom interference in metastatic breast cancer patients: a pilot randomized trial. Support Care Cancer. 2018;26(6):1993–2004.
  25. 25.
    Padrnos L, Kosiorek H, Scherber R, Knight E, Cuc A, Stonnington C, Dueck A, Geda Y, Mesa R. Myeloproliferative neoplasms and acceptance and commitment therapy: an ongoing feasibility study aimed at symptom mitigation and quality of life. EHA, 2018;(216851).Google Scholar
  26. 26.
    Van Dam NT, et al. Mind the hype: a critical evaluation and prescriptive agenda for research on mindfulness and meditation. Perspect Psychol Sci. 2018;13(1):36–61.CrossRefGoogle Scholar
  27. 27.
    Mesa RA, et al. Weight loss, splenomegaly, and hypocholesterolemia in myeloproliferative neoplasms: patterns and relevance from the Pre JAK2 inhibitor era 2009;114(22):3918–3918.Google Scholar
  28. 28.
    Mitrou PN, Kipnis V, Thiébaut AC, Reedy J, Subar AF, Wirfält E, et al. Mediterranean dietary pattern and prediction of all-cause mortality in a US population: results from the NIH-AARP Diet and Health Study. Arch Intern Med. 2007;167(22):2461–8.CrossRefGoogle Scholar
  29. 29.
    Chrysohoou C, Panagiotakos DB, Pitsavos C, Das UN, Stefanadis C. Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: the ATTICA Study. J Am Coll Cardiol. 2004;44(1):152–158.
  30. 30.
    Smidowicz A, Regula J. Effect of nutritional status and dietary patterns on human serum C-reactive protein and interleukin-6 concentrations. Adv Nutr. 2015;6(6):738–47.CrossRefGoogle Scholar
  31. 31.
    Kuriakose E. The JAK2V617F mutation seen in myeloproliferative neoplasms (MPNs) occurs in patients with inflammatory bowel disease: implications of a pilot study. Int J Clin Med. 2013;4:10–5.CrossRefGoogle Scholar
  32. 32.
    Scherber R, et al. Nutritional needs and preferences of myeloproliferative neoplasm patients: Phase I A of the NUTRIENT Study. EHA Abstract pending acceptance, 2017.Google Scholar
  33. 33.
    Scherber R, et al. Needs and preferences regarding nutrition and supplement use among individuals with myeloproliferative neoplasms. Proceedings of the 9th international congress on myeloproliferative neoplasms. 2017.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Hematology and OncologyMays MD Anderson Cancer Center at UT Health San AntonioSan AntonioUSA

Personalised recommendations